More than 50 researchers and scientists will be based at the R&D centre at Biocon Park in Bangalore, which is expected to open in June, it said.

Abbott said the new R&D center will focus on the development of nutrition products for maternal and child nutrition and diabetes care.

"India is a priority market for investment, growth and innovation," said Robert Miller, Divisional Vice President, Global R&D and Scientific Affairs for Abbott Nutrition.

"With malnutrition and common chronic diseases at their highest in this region, Abbott and Syngene have a common vision and commitment to support the development of a healthier India," Kiran Mazumdar-Shaw, Founder, Chairman and Managing Director, Biocon Group said.

Abbott India shares were seen trading at Rs 1,610, up 0.06% on the BSE, while the shares of Biocon were trading lower by 0.11% at Rs 237.40 at 11.10 am IST.

GoodReturns.in